Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.47 |
| ▸ | MMP9 | P14780 | 11/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 7/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876841 | 0.94 | MMP2 (0.46) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL877949 | 0.94 | MMP2 (0.46) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL877309 | 0.92 | MMP2 (0.51) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL874990 | 0.91 | MMP2 (0.44) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL875182 | 0.90 | MMP2 (0.51) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL878062 | 0.89 | MMP2 (0.49) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL877007 | 0.88 | MMP2 (0.47) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL874499 | 0.88 | MMP2 (0.53) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL878193 | 0.88 | MMP2 (0.48) | MMP2MMP9GPR139MMP3MMP13 | |
| SCHEMBL12472667 | 0.87 | GPR139 (0.44) | MMP2MMP9GPR139MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | claimed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | claimed |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | MMP2 17/4885MMP9 1/4885GPR139 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.